Literature DB >> 35353269

Skeletal muscle abnormalities in heart failure with preserved ejection fraction.

Matthew Anderson Md1, Clifton Forrest Parrott1, Mark J Haykowsky Ph D2, Peter H Brubaker Ph D3, Fan Ye Md1, Bharathi Upadhya Md4.   

Abstract

Almost half of all heart failure (HF) disease burden is due to HF with preserved ejection fraction (HFpEF). The primary symptom in patients with HFpEF, even when well compensated, is severe exercise intolerance and is associated with their reduced quality of life. Recently, studies showed that HFpEF patients have multiple skeletal muscle (SM) abnormalities, and these are associated with decreased exercise intolerance. The SM abnormalities are likely intrinsic to the HFpEF syndrome, not a secondary consequence of an epiphenomenon. These abnormalities are decreased muscle mass, reduced type I (oxidative) muscle fibers, and reduced type I-to-type II fiber ratio as well as a reduced capillary-to-fiber ratio, abnormal fat infiltration into the thigh SM, increased levels of atrophy genes and proteins, reduction in mitochondrial content, and rapid depletion of high-energy phosphate during exercise with markedly delayed repletion of high-energy phosphate during recovery in mitochondria. In addition, patients with HFpEF have impaired nitric oxide bioavailability, particularly in the microvasculature. These SM abnormalities may be responsible for impaired diffusive oxygen transport and/or impaired SM oxygen extraction. To date, exercise training (ET) and caloric restriction are some of the interventions shown to improve outcomes in HFpEF patients. Improvements in exercise tolerance following aerobic ET are largely mediated through peripheral SM adaptations with minimal change in central hemodynamics and highlight the importance of targeting SM to improve exercise intolerance in HFpEF. Focusing on the abnormalities mentioned above may improve the clinical condition of patients with HFpEF.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Exercise intolerance; HFpEF; Oxygen extraction; Skeletal muscle abnormalities; Skeletal myopathy

Year:  2022        PMID: 35353269     DOI: 10.1007/s10741-022-10219-9

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  61 in total

1.  Trends in prevalence and outcome of heart failure with preserved ejection fraction.

Authors:  Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

3.  Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.

Authors:  Mark J Haykowsky; Peter H Brubaker; Jerry M John; Kathryn P Stewart; Timothy M Morgan; Dalane W Kitzman
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

4.  Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.

Authors:  Bishnu P Dhakal; Rajeev Malhotra; Ryan M Murphy; Paul P Pappagianopoulos; Aaron L Baggish; Rory B Weiner; Nicholas E Houstis; Aaron S Eisman; Stacyann S Hough; Gregory D Lewis
Journal:  Circ Heart Fail       Date:  2014-10-24       Impact factor: 8.790

5.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Thomas P Olson; Carolyn S P Lam; Kelly S Flood; Amir Lerman; Bruce D Johnson; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2010-09-07       Impact factor: 24.094

6.  Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction.

Authors:  Paul S Bhella; Anand Prasad; Katja Heinicke; Jeff L Hastings; Armin Arbab-Zadeh; Beverley Adams-Huet; Eric L Pacini; Shigeki Shibata; M Dean Palmer; Bradley R Newcomer; Benjamin D Levine
Journal:  Eur J Heart Fail       Date:  2011-10-05       Impact factor: 15.534

7.  Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction.

Authors:  Mark J Haykowsky; Peter H Brubaker; Kathryn P Stewart; Timothy M Morgan; Joel Eggebeen; Dalane W Kitzman
Journal:  J Am Coll Cardiol       Date:  2012-07-10       Impact factor: 24.094

8.  Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction.

Authors:  Barry A Borlaug; Vojtech Melenovsky; Stuart D Russell; Kristy Kessler; Karel Pacak; Lewis C Becker; David A Kass
Journal:  Circulation       Date:  2006-11-06       Impact factor: 29.690

Review 9.  Chronotropic incompetence: causes, consequences, and management.

Authors:  Peter H Brubaker; Dalane W Kitzman
Journal:  Circulation       Date:  2011-03-08       Impact factor: 39.918

Review 10.  Heart failure with preserved ejection fraction: New approaches to diagnosis and management.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Clin Cardiol       Date:  2019-12-26       Impact factor: 2.882

View more
  1 in total

1.  Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.

Authors:  Ephraim B Winzer; Antje Schauer; Erik Langner; Antje Augstein; Keita Goto; Anita Männel; Peggy Barthel; Anett Jannasch; Siegfried Labeit; Norman Mangner; Axel Linke; Volker Adams
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.